Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Type Condition

    Boston, MA

    Search
    Boston, MA
    Show Map
    Map View
    Boston, MA

    Popular Searches

    By Condition

    Depression Clinical Trials in Massachusetts

    Anxiety Clinical Trials in Massachusetts

    Schizophrenia Clinical Trials in Massachusetts

    ADHD Clinical Trials in Massachusetts

    Bipolar Disorder Clinical Trials in Massachusetts

    Multiple Sclerosis Clinical Trials in Massachusetts

    Autism Clinical Trials in Massachusetts

    Treatment Resistant Depression Clinical Trials in Massachusetts

    Borderline Personality Disorder Clinical Trials in Massachusetts

    Social Anxiety Disorder Clinical Trials in Massachusetts

    Parkinson's Disease Clinical Trials in Massachusetts

    Alzheimer's Disease Clinical Trials in Massachusetts

    By Location

    Clinical Trials near Boston, MA

    Clinical Trials near Worcester, MA

    Clinical Trials near Springfield, MA

    Clinical Trials near Burlington, MA

    Clinical Trials near Fall River, MA

    Clinical Trials near Cambridge, MA

    Clinical Trials near North Dartmouth, MA

    Clinical Trials near Newton, MA

    Clinical Trials near Waltham, MA

    Clinical Trials near Watertown, MA

    Clinical Trials near Belmont, MA

    Clinical Trials near Brockton, MA

    Other People Viewed

    By Subject

    Top Clinical Trials near Boston, MA

    Top Depression Clinical Trials near Boston, MA

    Top Osteoarthritis Clinical Trials near Boston, MA

    Top Osteoporosis Clinical Trials near Boston, MA

    Top Weight Loss Clinical Trials near Boston, MA

    Top Colorectal Cancer Clinical Trials near Boston, MA

    Top Breast Cancer Clinical Trials near Boston, MA

    Top Lung Cancer Clinical Trials near Boston, MA

    Top Prostate Cancer Clinical Trials near Boston, MA

    Top Attention-Deficit/Hyperactivity Disorder (ADHD) Clinical Trials near Boston, MA

    Top Clinical Trials near Jamaica Plain, MA

    Top Clinical Trials near Attleboro, MA

    By Trial

    InTEGRA vs. MET/CBT for Youth with Alcoholism and Drug Use Disorder

    Healthy Diet for High Blood Pressure

    Topical Rapamycin for Vitiligo

    High-Dose Therapy and Autologous Stem Cell Transplant for Non-Hodgkin's Lymphoma

    Family Intervention Programs for Infant Development

    Spinal Cord Stimulation for Phantom Limb Pain

    Pembrolizumab + Sunitinib for Thymic Cancer

    Standardized Catheterization Assessment for Pulmonary Vein Stenosis

    Total Knee Replacement for Osteoarthritis

    Carbohydrate Fluids for Postoperative Nausea and Vomiting

    Pemigatinib + Atezolizumab + Bevacizumab for Bile Duct Cancer

    FITC-E2 CAR T Cells + Folate-Fluorescein for Osteosarcoma

    Related Searches

    Top Clinical Trials near Atlanta, GA

    Top Clinical Trials near Columbia, SC

    Top Clinical Trials near Wyoming

    High Intensity Exercise for Cerebral Palsy

    Vigabatrin for Post-anoxic Seizures

    IDECIDE-HOSPICE for Hospice Care Awareness

    Top Clinical Trials near Bellflower, CA

    mHealth Intervention for Cancer

    Antisense Oligonucleotide Treatment for Retinitis Pigmentosa

    rTMS Therapy for Depression

    Exercise for Myotonic Dystrophy

    Cancer Vaccine for BRCA Gene Mutation

    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      197 Clinical Paid Trials near Boston, MA

      Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Transcriptomic Skin Analysis for Atopic Dermatitis

      Boston, Massachusetts
      This is a multi-center, longitudinal study which will characterize the gene expression profiles and transcriptomic endotypes that underlie mild and moderate-severe Atopic dermatitis (AD) and will determine changes in these expression patterns and endotypes in response to standard-of-care treatment. Participants will complete up to ten scheduled study visits with assessment of topical steroid response and dupilumab response (if uncontrolled with topical steroids). Skin samples will be collected at all study visits to determine the gene expression profiles and transcriptomic endotypes that underlie mild vs. moderate-severe AD disease. The investigators will also evaluate the lipidomic, metabolomic, proteomic, and microbiome profiles of AD skin endotypes associated with mild and moderate-severe AD disease. Non-AD participants will serve as a control population. The primary objective of this study is to determine if the type 2-high non-lesional skin (skin tape) endotype is associated with current mild versus moderate-severe AD disease.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:HIV, Skin Diseases, Immunosuppression, Others
      Must Be Taking:Dupilumab

      433 Participants Needed

      Steroid During Surgery vs Eye Drops After Surgery for Retinal Detachment

      Boston, Massachusetts
      This trial is testing if a steroid injection around the eye during surgery can replace the usual post-surgery eye drops for patients with a specific type of retinal detachment. The injection aims to reduce swelling and inflammation. Steroid injections around the eye have been used to control inflammation and pain after eye surgeries, offering prolonged drug activity at the target tissue.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:40+

      Key Eligibility Criteria

      Disqualifiers:Glaucoma, Diabetic Retinopathy, Infections, Others
      Must Not Be Taking:Corticosteroids

      168 Participants Needed

      Dexamethasone for Knee Surgery

      Somerville, Massachusetts
      The purpose of this study is to determine the most efficacious and safest dexamethasone dose given intraoperatively during total knee arthroplasty that reduces postoperative opioid consumption and pain, improves postoperative nausea and vomiting, and minimizes postoperative complications.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Inflammatory Arthritis, Renal Or Liver Failure, Others
      Must Not Be Taking:Corticosteroids

      404 Participants Needed

      Anabolic Therapy for Osteoporosis

      Boston, Massachusetts
      In this research study we want to learn more about the effect of two different FDA-approved medications in the treatment of osteoporosis.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4
      Age:45+
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Kidney Disease, Hypercalcemia, Malignancy, Others
      Must Not Be Taking:Bisphosphonates, Denosumab, Estrogens, Others

      50 Participants Needed

      Ultrasound Therapy for Cardiac Amyloidosis

      Boston, Massachusetts
      This is a prospective pilot clinical study of subjects with cardiac amyloidosis and control subjects without amyloidosis where we plan to evaluate changes in myocardial blood flow, systolic and diastolic function before and after sonotherapy.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Heart Disease, Valve Issues, Lung Disease, Others

      70 Participants Needed

      Methylphenidate for Epilepsy-Related Cognitive Deficits

      Boston, Massachusetts
      Methylphenidate (MPH) is a stimulant, FDA-approved for the treatment of attention deficit hyperactivity disorder (ADHD). It is unknown, however, if stimulants would be of benefit for memory and thinking problems due to epilepsy. In this study, participants will be assigned randomly (i.e., by flip of a coin), to a group that takes MPH and a group that takes a placebo (sugar pill). Participants will not know the group to which they have been assigned. Tests of attention and memory will be completed before taking the study pills and at Week 8. All participants will then have the option of taking MPH for the next two months, and attention and memory will be tested again at Week 16. The study will determine whether methylphenidate is helpful for the treatment of attention and memory problems in adults with epilepsy, and whether the medication is safe and beneficial when taken over an extended time period.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Psychotic Disorders, Severe Anxiety, Bipolar, Others
      Must Not Be Taking:MAOIs, Erectile Dysfunction Meds

      226 Participants Needed

      Atorvastatin for Preventing Dementia

      Boston, Massachusetts
      PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:75+

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular Disease, Dementia, ADL Dependence, Others
      Must Not Be Taking:Statins

      20000 Participants Needed

      Quillivant XR for ADHD in Down Syndrome

      Boston, Massachusetts
      Children with Down syndrome (DS) have a 3-5 time greater prevalence of Attention Deficit Hyperactivity Disorder (ADHD) than typically developing (TD) children. Despite this higher risk of ADHD, rates of stimulant medication treatment are disproportionately low in children with DS+ADHD, even though stimulants are the most efficacious ADHD treatment and are recommended by consensus guidelines for use in children with intellectual disability and ADHD. The investigators propose the first randomized clinical trial (RCT) of stimulant medication in children with DS+ADHD. This RCT may provide evidence regarding the short- and long-term safety and efficacy of stimulant use in children with DS+ADHD, both with and without CHD. All children enrolled in the study will complete a comprehensive assessment battery evaluating ADHD diagnostic criteria, as well as behavioral, cognitive, academic, and functional impairments.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:6 - 17

      Key Eligibility Criteria

      Disqualifiers:Psychoses, Bipolar, Organic Brain Injury, Heart Conditions, Severe OSA, Pregnancy, Others
      Must Not Be Taking:ADHD Stimulants, MAOIs

      100 Participants Needed

      Gardasil 9 Vaccination Regimen for HPV

      Boston, Massachusetts
      The goal of this study is to explore and evaluate whether a 2-dose schedule of Gardasil 9 among young and mid-adult women 16-45 years of age is generally safe and immunogenic, with an antibody response that is not inferior to that observed of a 3-dose schedule of Gardasil 9 among women aged 16-26 years old. The investigators thought that having a 2-dose vaccination regimen for individuals 16 to 45 would provide a more robust dataset than those of 27 to 45 years old.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4
      Age:16 - 45
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Prior HPV Vaccination, Immunocompromised, Others

      352 Participants Needed

      Megestrol for Feeding Disorders in Children

      Boston, Massachusetts
      This is a multi-center, randomized, placebo-controlled, double-blind clinical trial. The primary focus of the study is the evaluation of the effectiveness of treatment with megestrol as part of a 24 week behavioral feeding protocol in transitioning from tube to oral feedings in a pediatric population. Approximately 60 pediatric subjects matching the criteria for eligibility will be enrolled in the study and randomized to receive either megestrol (n=30) or placebo (n=30).

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4
      Age:9+

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      71 Participants Needed

      Physical Therapy and Steroids for Frozen Shoulder

      Boston, Massachusetts
      This trial compares two treatments for frozen shoulder: one with physical therapy and steroid injections, and the other with just steroid injections followed by observation. It aims to see if physical therapy offers extra benefits and if the cost is justified. The study focuses on adults with frozen shoulder to find the most effective and economical treatment.
      Stay on current meds
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Non-English, Pregnant, Prior Surgery, Others

      260 Participants Needed

      Optimal Heart Failure Therapy for Heart Failure

      Boston, Massachusetts
      This trial is testing two remote care methods to improve medication plans for heart failure patients. One method uses a virtual clinic with a step-by-step approach, and the other focuses on education and remote management. The goal is to find out which method helps doctors prescribe the best medications.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Low Blood Pressure, Aortic Stenosis, Amyloid Heart Disease, Others
      Must Be Taking:ARNi, SGLT2i

      500 Participants Needed

      Spironolactone vs Doxycycline for Acne

      Boston, Massachusetts
      This trial compares two treatments for women with moderate to severe acne. One treatment helps balance hormones to reduce skin oiliness, while the other kills bacteria and reduces inflammation. The goal is to see which treatment is more effective and potentially reduce the need for long-term antibiotic use.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4
      Age:16 - 40
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Heart Disease, Renal Disease, Others
      Must Not Be Taking:Ace Inhibitors, Arbs, Nsaids, Digoxin

      350 Participants Needed

      Acellular Dermal Matrix for Gum Recession

      Boston, Massachusetts
      Gingival recession is a common defect among the American population. It is also a major cause for root decay, hypersensitivity, contributes to tooth mobility and low self-esteem. Acellular dermal matrix, a human-derived grafting material has been put on the market for the treatment of gingival recession. Treating gingival recession with this material has been a validated treatment option for years. However, treatment outcomes in two patient populations, namely those with thin biotypes and those with thick biotypes, has not been investigated. This study will observe the primary treatment outcomes in the two patient groups at 5 time points - 3 months, 6 months and 12 months post-surgery to observe short term outcomes; additional 24 months and 48 months post-surgery to observe long term outcomes.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Immunosuppression, Smoking, Others
      Must Not Be Taking:Immunosuppressants

      34 Participants Needed

      Saxenda for Obesity

      Boston, Massachusetts
      The purpose of this protocol is to investigate the effect of treatment with the study drug Liraglutide, a GLP-1 receptor agonist, on centers of the brain that control appetite and food intake.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Renal Impairment, Hepatic Impairment, Others
      Must Not Be Taking:Warfarin, Steroids, Hormones, Others

      28 Participants Needed

      Lorcaserin for Obesity

      Boston, Massachusetts
      The purpose of this protocol is to investigate, using functional magnetic resonance imaging (fMRI), the effect of treatment with lorcaserin on centers of the brain that control appetite and food intake, as well as lorcaserin's downstream metabolic effects.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Renal Impairment, Hepatic Impairment, Others
      Must Not Be Taking:Weight Loss Drugs, Antidepressants, Steroids, Others

      40 Participants Needed

      ST-067-001 for Solid Tumors

      Boston, Massachusetts
      This trial is testing a new drug called ST-067 on patients with certain types of cancer that have not responded to previous treatments. The goal is to find the safest and most effective dose and to see how well it works against these cancers.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disorders, Brain Metastases, Cardiovascular Disease, Others
      Must Not Be Taking:Immunosuppressants, Corticosteroids

      316 Participants Needed

      Zipalertinib for Non-Small Cell Lung Cancer

      Boston, Massachusetts
      This trial is testing CLN-081, a new drug, in patients with a specific type of lung cancer that has a genetic mutation. The drug aims to block a protein that helps cancer cells grow, to see if it can slow down or stop the cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:COVID-19 Pneumonitis, Brain Metastases, Cardiac Conditions, Others
      Must Not Be Taking:CYP3A Inhibitors, P-gp Inducers

      284 Participants Needed

      NPC1 for Alzheimer's Disease

      Boston, Massachusetts
      The goal of this early phase, open-label, single arm clinical trial is to determine the 6-month effects and tolerability of NPC1 (parthenolide and ipriflavone) on biomarkers of Alzheimer's Disease among adults with objective indicators of seeding AD pathology that also have subjective cognitive concerns, Mild Cognitive Impairment, or Alzheimer's Disease (AD)

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 1, 2
      Age:55+

      Key Eligibility Criteria

      Disqualifiers:CNS Disease, Substance Abuse, Cancer, Others
      Must Be Taking:Acetylcholine Esterase Inhibitors, NMDA Antagonists

      40 Participants Needed

      MT1988 for High Risk of Psychosis

      Boston, Massachusetts
      The goal of this clinical trial is to learn how tests undertaken by people at high risk of developing psychosis (aged 17 to 30 years old) change when those people are given the study drug MT1988 daily for 8 weeks. This will help identify tests that could be used in later trials developing treatments for symptoms in people at high risk of developing psychosis, to measure whether those new treatments are effective. The main question this trial aims to answer is: Can any of the tests (biomarkers) used in this study detect changes in participants dosed with one of two different dose levels of MT1988? Researchers will compare the results from two dose levels of MT1988 to a placebo group. Researchers do not expect to see the test results change in participants taking placebo and this will be compared to changes expected in test results in participants taking MT1988. Participants will: * take a dose of MT1988 or placebo twice per day for 8 weeks * attend clinic appointments every two weeks to undertake assessments * report any side effects they experience to the researchers

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 1, 2
      Age:17 - 30

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Cognitive Disorder, Suicide Risk, Others
      Must Not Be Taking:Antipsychotics, Others

      150 Participants Needed

      Why Other Patients Applied

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31
      Match to a Trial

      Elacestrant + Trastuzumab Deruxtecan for Breast Cancer

      Boston, Massachusetts
      The goal of this study is to evaluate the safety and efficacy of elacestrant in combination with trastuzumab deruxtecan (T-DXd) in participants with hormone receptor-positive (HR+), HER2-low or HER2-ultralow, metastatic breast cancer that is resistant to prior CDK4/6 inhibitor and endocrine therapy. The names of the study drugs involved in this study are: * Elacestrant (a type of selective estrogen receptor degrader) * Trastuzumab deruxtecan (a type of standard of care antibody drug conjugate)
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Symptomatic Brain Metastases, Active Tuberculosis, Others
      Must Be Taking:GnRH Agonist

      65 Participants Needed

      Tagraxofusp + Venetoclax + Azacitidine for Acute Myeloid Leukemia

      Boston, Massachusetts
      The purpose of this research study is to test the safety and efficacy of a new drug combination with three agents, azacitidine, venetoclax and tagraxofusp. Leftover (residual) leukemia disease that is not visible by eye can be increase the chance of disease recurrence. This research study is to determine if the combination therapy can safely help to control residual Acute Myeloid Leukemia (AML) and to prevent disease recurrence. The names of the study drugs involved in this study are: * Tagraxofusp (a type of CD123-directed cytotoxin) * Azacitidine (a type of standard of care cytidine nucleoside analog) * Venetoclax (a type of standard of care BCL-2 inhibitor)
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Acute Promyelocytic Leukemia, SCT, Others
      Must Not Be Taking:CD123-targeted Therapy, CYP3A Inducers

      31 Participants Needed

      Shared Decision-Making Toolkit for Breast Cancer

      Boston, Massachusetts
      This study evaluates the effectiveness of a Shared Decision-Making (SDM) toolkit designed to support older breast cancer survivors aged 80 and above in making informed decisions about continuing surveillance mammography.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 2
      Age:80+
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Metastatic Cancer, Hospice, Psychiatric Illness, Others
      Must Be Taking:Hormonal Therapy, CDK 4/6 Inhibitors

      364 Participants Needed

      Allopregnanolone for Post-Traumatic Stress Disorder

      Boston, Massachusetts
      Purpose: About 6.4% of the U.S. population suffers from posttraumatic stress disorder (PTSD). Trauma-focused psychotherapies are generally effective in PTSD, but responses vary greatly across individuals and PTSD subpopulations. Neurobiological factors impacted by life experiences, stress, and genetics can affect treatment responses. These factors can alter brain capacities needed to reprocess traumatic memories prevent them from triggering intensely distressing, disruptive, out-of-place responses. For example, during psychotherapy for PTSD, trauma memory activation engages two competing brain processes that affect recovery: "extinction" versus "reconsolidation" of trauma-related emotional, physiological, and behavioral responses. This study tests whether a single intravenous (IV) dose of allopregnanolone (Allo) compared to placebo (which is non-active): promotes consolidation of extinction learning (sub-study 1) or blocks reconsolidation of physiological responses triggered by aversive memories (sub-study 2). The study also tests whether Allo compared to placebo affects retention of non-aversive memories.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:Substance Use Disorder, Bipolar, Schizophrenia, Severe TBI, Others
      Must Not Be Taking:Opiates, Benzodiazepines, Hormone Therapy, Others

      96 Participants Needed

      Mosunetuzumab for Chronic Lymphocytic Leukemia

      Boston, Massachusetts
      The goal of this study is to test mosunetuzumab given alone or in combination with a Bruton tyrosine kinase inhibitor (BTKi, such as ibrutinib, acalabrutinib, zanubrutinib, or pirtobrutinib) in participants with CLL (chronic lymphocytic leukemia) or small lymphocytic lymphoma (SLL). The names of the study drugs in this research study are: * Mosunetuzumab * BTK inhibitor: Ibrutinib, acalabrutinib, zanubrutinib, or pirtobrutinib
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Bulky Disease, CNS Disease, Cardiovascular, Others
      Must Be Taking:BTK Inhibitors

      40 Participants Needed

      VS-7375 + Cetuximab for Solid Tumors

      Boston, Massachusetts
      This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, Uncontrolled Diseases, Others
      Must Not Be Taking:KRAS G12D Inhibitors

      330 Participants Needed

      ST-503 for Small Fiber Neuropathy

      Boston, Massachusetts
      This research is being done to study a possible treatment for refractory pain due to small fiber neuropathy (SFN). ST-503 is intended to deliver a modified copy of the gene which will ideally repress Nav1.7 tissue-related pain signals reaching the brain, which should reduce the refractory pain due to small fiber neuropathy (SFN).

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Alcohol Abuse, Drug Abuse, Cancer, Others
      Must Not Be Taking:Cannabinoids, Hepatotoxic Medications

      27 Participants Needed

      Gene Therapy for Spastic Paraplegia

      Boston, Massachusetts
      Safety and Efficacy of AAV9/AP4B1 For Patients with AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47): A Phase 1/2 Single-Center, Open-Label Study of Stereotactic Intra-cisterna Magna Administration. The goal of this clinical trial is to evaluate whether a gene therapy can safely treat children with SPG47, a rare genetic condition that causes progressive spasticity and developmental delays. The main questions it aims to answer are: * Is the gene therapy safe and well tolerated? * Does the gene therapy improve motor function and developmental outcomes? Participants will: * Undergo screening assessments to confirm eligibility * Receive a single dose of the gene therapy vector * Attend follow-up visits for safety monitoring and developmental assessments over the course of five years
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 1, 2
      Age:12 - 60

      Key Eligibility Criteria

      Disqualifiers:Cardiomyopathy, CNS Impairment, Others
      Must Be Taking:Anti-spasticity, Anti-epileptic

      5 Participants Needed

      SB-007 for Stargardt Disease

      Boston, Massachusetts
      This Phase 1/2 study will evaluate the safety, tolerability, and preliminary efficacy of subretinal SB-007 administration to determine dose selection in subjects with Stargardt's Type 1 (STGD1). This is a multicenter study which will enroll approximately 57 subjects, followed up over a 96 week period post treatment after a single administration of SB-007.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:12 - 65

      Key Eligibility Criteria

      Disqualifiers:Intraocular Surgery, Amblyopia, Others
      Must Not Be Taking:Vitamin A, Retinoids

      57 Participants Needed

      EIK1004 for Cancer

      Boston, Massachusetts
      This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer (mCRPC) and pancreatic cancer with deleterious/suspected deleterious mutations of select homologous recombination repair (HRR) genes. Condition or disease Intervention/treatment Phase Advanced Solid Tumors Drug: EIK1004 (IMP1707) Phase 1/Phase 2
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Infections, Bleeding, Gastrointestinal, Others
      Must Be Taking:ADT

      130 Participants Needed

      123...7

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do clinical trials in Boston, MA pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do clinical trials in Boston, MA work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Boston, MA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Boston, MA is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Boston, MA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a medical study in Boston, MA?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest clinical trials in Boston, MA?

      Most recently, we added Elacestrant + Trastuzumab Deruxtecan for Breast Cancer, Tagraxofusp + Venetoclax + Azacitidine for Acute Myeloid Leukemia and Shared Decision-Making Toolkit for Breast Cancer to the Power online platform.